Tango Therapeutics Shuts Early-Stage Cancer Study Due To Liver Toxicity [Yahoo! Finance]
Tango Therapeutics, Inc. (TNGX)
Company Research
Source: Yahoo! Finance
“Patient safety is always our first priority and based on emerging data from the TNG348 dose escalation study, we have made the decision to discontinue further development of this molecule due to liver toxicity experienced by patients in the trial. While disappointing, we believe this is the right decision given the data at hand,” said Barbara Weber, President and CEO. “We will focus resources and capital on our existing portfolio, particularly our PRMT5 program. We remain committed to and confident in our ability to deliver a comprehensive clinical update on TNG908 and TNG462 in the second half of this year.” TNG348 was being studied in a phase 1/2 clinical trial evaluating the safety, pharmacokinetics, pharmacodynamics, and efficacy as a single agent and in combination with AstraZeneca Plc's (NASDAQ: AZN ) Lynparza (olaparib) in patients with BRCA1/2-mutant and other HRD+ (homologous recombination deficient) cancers. Grade 3/4 liver function abnormalities were observed in pat
Show less
Read more
Impact Snapshot
Event Time:
TNGX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TNGX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TNGX alerts
High impacting Tango Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
TNGX
News
- Tango Therapeutics (TNGX) Moves 10.3% Higher: Will This Strength Last? [Yahoo! Finance]Yahoo! Finance
- Tango Therapeutics to Present at the Goldman Sachs 45th Annual Global Healthcare ConferenceBusiness Wire
- Tango Therapeutics, Inc. (NASDAQ: TNGX) was upgraded by analysts at Guggenheim to a "strong-buy" rating.MarketBeat
- Tango Therapeutics, Inc. (NASDAQ: TNGX) had its price target lowered by analysts at HC Wainwright from $16.00 to $13.00. They now have a "buy" rating on the stock.MarketBeat
- Tango Therapeutics, Inc. (NASDAQ: TNGX) had its price target lowered by analysts at Guggenheim from $16.00 to $14.00. They now have a "buy" rating on the stock.MarketBeat
TNGX
Earnings
- 11/8/23 - Beat
TNGX
Sec Filings
- 6/7/24 - Form 4
- 6/7/24 - Form 4
- 6/7/24 - Form 4
- TNGX's page on the SEC website